Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus albumin-bound paclitaxel in second-line extensive-stage small cell lung cancer
ChiCTR2300068627Phase 2Not yet recruiting
- Sponsor
- Huzhou Central Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and paclitaxel in small cell lung cancer (SCLC), sponsored by Huzhou Central Hospital. Primary endpoint: Progression-free survival. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
anlotinibpaclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300068627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068627.